[Myositis as a post-acute sequela of COVID-19 disease? : Even in times of the pandemic, muscle biopsies can only be assessed in the context of accurate clinical information]. / Myositis als postakute Folge einer COVID-19-Erkrankung? : Auch in Zeiten der Pandemie können Muskelbiopsien oft nur im Kontext einer genauen Weitergabe klinischer Informationen beurteilt werden.

A case of a patient suffering from COVID-19 with suspected associated myositis is reported, in which the initially limited information about the history and disease course led to difficulties in establishing a reasonable diagnosis. Through inquiry, further data could be collected, so that the diagnosis of an infection-associated thrombotic microangiopathy in the context of a Morganella morganii myositis could be made. This patient study shows that even in times of the omnipresent pandemic and despite the context of a positive COVID-19 test result, differential diagnoses and the integrative clinicopathologic approach in interpreting muscle biopsy findings should not be neglected.

Thrombolysis in patients with prior stroke within the last 3 months.

BACKGROUND AND PURPOSE: Patients with prior stroke within 3 months have been mostly excluded from randomized thrombolysis trials mainly because of the fear of an increased rate of symptomatic intracerebral hemorrhage (sICH). The aim of this study was to compare baseline characteristics and clinical outcome of thrombolyzed patients who had a previous stroke within the last 3 months with those not fulfilling this criterion (comparison group). METHODS: In all, 1217 patients were included in our analysis (42.2% women, mean age 68.8 ± 14.4 years). RESULTS: Patients with previous stroke within the last 3 months (17/1.4%) had more often a basilar artery occlusion (41.2% vs. 10.8%) and less frequently a modified Rankin scale (mRS) score 0-1 prior to index stroke (88.2% vs. 97.3%) and a higher mean time lapse from symptom onset to thrombolysis (321 min vs. 262 min) than those in the comparison group. Stroke severity was not different between the two groups. Rates of sICH were 11.8% vs. 6%. None of the sICHs and only one asymptomatic intracerebral hemorrhage occurred in the region of the former infarct. At 3 months, favorable outcome (mRS ≤ 2) in patients with previous stroke within 3 months was 29.4% (vs. 48.9%) and mortality 41.2% (vs. 22.7%). CONCLUSIONS: In patients with prior stroke within the last 3 months, none of the sICHs and only one asymptomatic intracerebral hemorrhage occurred in the region of the former infarct. The high mortality was influenced by four patients, who died until discharge due to acute major index stroke. It is reasonable to include these patients in randomized clinical trials and registries to assess further their thrombolysis benefit-risk ratio.

Stent-retriever thrombectomy: impact on the future of interventional stroke treatment.

Endovascular treatment for acute ischemic stroke has evolved in the past years. The current development of stent-retriever thrombectomy is a landmark in the clinical treatment and study results of acute ischemic stroke. This review summarizes the recent study results, elucidates the shortcomings of endovascular stroke treatment, and takes the opportunity for an outlook on the role of stroke interventions in the future.

[Mechanical thrombectomy for acute ischemic stroke]. / Mechanische Thrombektomie beim akuten Schlaganfall.

The therapy of acute ischemic stroke aims at fast recanalization of the occluded brain vessel. In contrast to intravenous thrombolysis (IVT), endovascular approaches yield higher recanalization rates especially in large vessel occlusions. Mechanical thrombectomy with the Merci Retriever received FDA approval in 2004 as an adjunct to IVT or in the case of failed recanalization after IVT. The time window for treatment is 8 h from stroke onset. However, the recanalization rate was 55 %, still leaving space for further improvement. In addition to the Merci Retriever, the Penumbra System received FDA approval in 2008. The newest endovascular approach comprising retrievable intracranial stents results in an increased recanalization rate exceeding 90 % and has markedly reduced the time to recanalization. On the other hand, the complication rate has not increased yet. These promising results suggest a combined therapy for acute ischemic stroke. In a first step IVT can be started independently of the size of the treating hospital and in a next step the patient is transferred to a neuroradiological center. If vessel occlusion persists, additional endovascular recanalization is performed (bridging concept). Patients who don't qualify for IVT are candidates for mechanical thrombectomy up to 8 h after stroke onset.

Low-dose temporal bone CT in infants and young children: effective dose and image quality.

BACKGROUND AND PURPOSE: The temporal bone is ideal for low-dose CT because of its intrinsic high contrast. The aim of this study was to retrospectively evaluate image quality and radiation doses of a new low-dose versus a standard high-dose pediatric temporal bone CT protocol and to review dosimetric data from the literature. MATERIALS AND METHODS: Image quality and radiation doses were compared for 38 low-dose (80 kV/90-110 mAs) and 16 high-dose (140 kV/170 mAs) temporal bone CT scans of infants to 5-year-old children. The CT visualization quality of 23 middle and inner ear structures was subjectively graded by 3 neuroradiologists and 3 otologists by using a 5-point scale with scores 1-2 indicating insufficient and scores 3-5 indicating sufficient image quality. Effective doses of local and literature-derived protocols were calculated from dosimetric data by using NRPB-SR250 software. RESULTS: Insufficient image-quality scores were more frequent in low-dose scans versus high-dose scans, but the difference was only statistically significant for otologists (6.0% versus 3.4%, P = .004) and not for neuroradiologists (1.2% versus 0.7%, P = .84). Image quality was critical for small structures (such as the stapes or lamella at the internal auditory canal fundus). Effective doses were 0.25-0.3 mSv for low-dose scans, 1.4-1.8 mSv for high-dose scans, and 0.9-2.6 mSv for literature-derived protocols. CONCLUSIONS: The image quality of the new low-dose protocol remains diagnostic for assessing middle and inner ear anatomy despite a 3- to 8-fold dose reduction over previous and literature-derived protocols. However, image quality of small structures is critical and may be perceived as insufficient.